Lucknow – A recent audit by the Uttar Pradesh Food Safety and Drug Administration (FSDA) has uncovered a striking disparity between the amounts hospitals actually spend on medicines and the maximum retail prices (MRP) printed on those products. In several instances, the MRP is dozens of times the price paid by the hospital pharmacy.

Scope of the investigation

The review examined purchase records from 214 pharmacies operating within medical colleges and private hospitals. Out of 130 medicines surveyed, 36 items displayed an MRP more than tenfold higher than their procurement cost. The most extreme case showed an MRP roughly 67 times the purchase price.

Polymyxin‑B injection leads the list

The greatest mismatch involved a Polymyxin‑B injection, a drug used to combat severe bacterial infections. Hospitals bought the vial for ₹74.09, yet the label printed an MRP of ₹4,980.94 – a gap of almost 67 times.

Wide variations in critical injectable medicines

Other high‑impact injectables also showed stark differences. A medication for advanced liver disease was procured at about ₹56 but carried an MRP of ₹3,050. Similar mismatches appeared in drugs targeting serious bacterial and fungal infections.

Meropenem and Caspofungin price spreads

For Meropenem 1 g, a staple against hard‑to‑treat bacterial infections, the MRP ranged from roughly 5.3 to 10 times the purchase price, depending on the brand.

Caspofungin 70 mg, an antifungal agent, displayed the most pronounced gap among the group. One formulation cost the hospital ₹800 but was marked at ₹21,230 (about 26.5 ×). Another batch was bought for ₹897.75 and labeled at ₹19,892.

Cancer and life‑saving drugs also under scrutiny

The audit flagged several oncology and other life‑saving medicines with similarly inflated MRPs. While high printed prices can provide manufacturers room for discounts, the findings raise concerns about how these figures are set and communicated to patients.

Medical devices mirror the trend

Price inflation was not confined to pharmaceuticals. A three‑way stopcock was bought for just ₹6.40 yet bore an MRP of ₹163. Another piece of equipment cost the hospital ₹20.95 but carried a retail label of ₹500.

Limited availability squeezes patient choice

When a drug is stocked only in a specific hospital pharmacy—or is scarce on the open market—patients have little leverage to compare prices. Consequently, they may be compelled to purchase the medication at the inflated hospital‑pharmacy rate, potentially inflating overall treatment costs.

Implications for transparency and regulation

The FSDA’s findings have intensified calls for greater pricing transparency, stricter procurement oversight, and regular monitoring of MRPs for both medicines and medical consumables. Clearer insight into the relationship between purchase costs and retail prices could help curb excessive mark‑ups and protect patients from undue financial burden.